Zydus Takes Aim At Three Rivers’ Hep C Patent

Law360, New York (May 18, 2007, 12:00 AM EDT) -- Generic drug company Zydus Pharmaceuticals USA Inc. has shot back at drug maker Three Rivers Pharmaceuticals LLC, asserting that its ribavirin caplets and tablets do not infringe Three Rivers’ patent for its hepatitis C drug.

Zydus filed a response Thursday to the suit Three Rivers filed in April in the U.S. District Court for the Eastern District of Virginia, seeking declaratory judgment that Three Rivers’ patent is invalid and unenforceable.

The patent covers a method for producing ribavirin pellets, which Three Rivers markets and sells under...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.